Market Overview

UBS Cuts Price Target On Celgene To $146 As GED Drops Out

Share:
UBS Cuts Price Target On Celgene To $146 As GED Drops Out

The discontinuation of Celgene Corporation (NASDAQ: CELG)’s mongerson for Crohn’s disease prompted a 6.6-percent sell-off in Friday’s premarket trading.

But UBS was undeterred by the announcement.

“Looking forward, we are still encouraged by the prospects for this next product cycle (ozanimod and luspatercept) for Celgene,” analysts Carter Gould, Jeffrey Hung and Andrea Brettler wrote in a note. “While there is more priced in there (we model peak sales of $4.2B and $2.5B, respectively), there are defined paths to upside (Crohn's, myelofibrosis, broader MDS) with some clinical data in hand.”

UBS maintains a Buy rating on the stock while lowering its price target from $153 to $146.

What About Mongerson?

The analysts had long registered skepticism of the abandoned candidate’s potential in Crohn’s. Earlier studies triggered enduring questions about patient selection, endoscopic response data and impact on C-reactive protein levels, according to UBS.

Celgene’s shift from mongerson, or GED-0301, is not entirely certain, as the company continues the drug’s Phase 2 trials for ulcerative colitis, but UBS removed candidate from its model entirely. The cut justified a $7 drop in price target and a decrease in 2020 earnings per share estimates from $13.17 to $13.10.

At the time of publication, Celgene was set to open at $127, down from Thursday’s closing rate of $135.96.

Related Link: 4 Biotech Stocks Initiated At A Buy: Acceleron, Tesaro, Mirati, Fate

Latest Ratings for CELG

DateFirmActionFromTo
Nov 2019Standpoint ResearchDowngradesBuyHold
Nov 2019BairdDowngradesOutperformNeutral
May 2019BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Price Target Reiteration Analyst Ratings Movers Best of Benzinga

Latest Ratings

StockFirmActionPT
INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com